Trial Profile
Dose finding study for effective reversal of a moderate rocuronium-induced neuromuscular block with sugammadex in morbidly obese patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jul 2021
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- Acronyms BRIDION
- 14 Jul 2021 New source identified and integrated ClinicalTrials.gov: (US National Institutes of Health: NCT01911520).
- 07 Jul 2021 Status changed from recruiting to completed.
- 12 Sep 2014 New trial record